EP
AARD

Essential Partners’s Aardvark Therapeutics AARD Stock Holding History

Essential Partners’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.93K Sell
509
-559
-52% -$2.61K ﹤0.01% 1803
2026
Q1 		$4.03K Buy
+1,068
New +$11.1K ﹤0.01% 1687

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Essential Partners's AARD Position: Q2 2026 in Review

Essential Partners reduced its Aardvark Therapeutics (AARD) stake by 52% in Q2 2026, selling an estimated $2.61K and leaving 509 shares worth $2.93K. The position accounts for ﹤0.01% of the portfolio, ranked #1803.

Essential Partners first reported a position in AARD in Q1 2026 and has held it in 2 quarters since. The position peaked at $4.03K in Q1 2026. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Essential Partners held 509 shares of Aardvark Therapeutics worth $2.93K as of Q2 2026.
  • Essential Partners sold 559 Aardvark Therapeutics shares in Q2 2026, an estimated $2.61K.
  • Aardvark Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1803 holding.
  • Essential Partners first reported a position in Aardvark Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Essential Partners's Aardvark Therapeutics position peaked at $4.03K in Q1 2026.
  • 71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.